{"id":31813,"date":"2025-04-15T13:29:24","date_gmt":"2025-04-15T05:29:24","guid":{"rendered":"https:\/\/flcube.com\/?p=31813"},"modified":"2025-04-15T13:29:25","modified_gmt":"2025-04-15T05:29:25","slug":"hightide-therapeutics-htd1801-shows-positive-phase-iii-results-in-type-2-diabetes-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31813","title":{"rendered":"HighTide Therapeutics&#8217; HTD1801 Shows Positive Phase III Results in Type 2 Diabetes Treatment"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">China-based HighTide Therapeutics Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/2511:HKG\">HKG: 2511<\/a>) has announced positive results from two Phase III clinical studies (SYMPHONY-1 and SYMPHONY-2) for its drug candidate HTD1801 (berberine ursodeoxycholate, BUDCA) in treating type 2 diabetes (T2DM). Both studies achieved their primary endpoints, demonstrating significant improvements in glycemic control and supporting the filing of a New Drug Application (NDA) in China within this year.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>SYMPHONY Studies: Design and Outcomes<\/strong><br>The SYMPHONY-1 study evaluated the efficacy and safety of HTD1801 in T2DM patients with poor blood glucose control despite dietary and exercise interventions. The SYMPHONY-2 study focused on T2DM patients with inadequate glycemic control on metformin. Both trials were multi-center, randomized, double-blind, and placebo-controlled. After 24 weeks of treatment, HTD1801 showed a statistically significant reduction in HbA1c levels compared to placebo, with continuous improvement observed throughout the treatment period. These results highlight HTD1801\u2019s potential for sustained glucose metabolism improvement.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mechanism and Safety Profile<\/strong><br>HTD1801 is an oral anti-inflammatory and metabolic modulator designed to treat metabolic and digestive system diseases. Beyond improving glycemic control, the drug demonstrated reductions in inflammatory markers closely associated with cardiovascular events in T2DM patients, including glutamyl transferase (GGT) and high-sensitivity C-reactive protein (hsCRP). HTD1801 also exhibited a favorable safety and tolerability profile, with no significant risk of hypoglycemia, addressing a critical concern in diabetes management.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Market Implications<\/strong><br>The positive data from the SYMPHONY studies position HTD1801 as a promising new therapy for T2DM patients, particularly those with unmet needs in glycemic control. HighTide Therapeutics plans to submit an NDA in China this year, marking a significant step toward bringing this innovative treatment to market and potentially reshaping the landscape of diabetes care.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based HighTide Therapeutics Inc. (HKG: 2511) has announced positive results from two Phase III clinical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":31814,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[17,39,610,1309],"class_list":["post-31813","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-results","tag-diabetes","tag-hightide-therapeutics","tag-hkg-2511"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>HighTide Therapeutics&#039; HTD1801 Shows Positive Phase III Results in Type 2 Diabetes Treatment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based HighTide Therapeutics Inc. (HKG: 2511) has announced positive results from two Phase III clinical studies (SYMPHONY-1 and SYMPHONY-2) for its drug candidate HTD1801 (berberine ursodeoxycholate, BUDCA) in treating type 2 diabetes (T2DM). Both studies achieved their primary endpoints, demonstrating significant improvements in glycemic control and supporting the filing of a New Drug Application (NDA) in China within this year.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31813\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HighTide Therapeutics&#039; HTD1801 Shows Positive Phase III Results in Type 2 Diabetes Treatment\" \/>\n<meta property=\"og:description\" content=\"China-based HighTide Therapeutics Inc. (HKG: 2511) has announced positive results from two Phase III clinical studies (SYMPHONY-1 and SYMPHONY-2) for its drug candidate HTD1801 (berberine ursodeoxycholate, BUDCA) in treating type 2 diabetes (T2DM). Both studies achieved their primary endpoints, demonstrating significant improvements in glycemic control and supporting the filing of a New Drug Application (NDA) in China within this year.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31813\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-15T05:29:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-15T05:29:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1504-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31813#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31813\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HighTide Therapeutics&#8217; HTD1801 Shows Positive Phase III Results in Type 2 Diabetes Treatment\",\"datePublished\":\"2025-04-15T05:29:24+00:00\",\"dateModified\":\"2025-04-15T05:29:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31813\"},\"wordCount\":291,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31813#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1504-png.webp\",\"keywords\":[\"Clinical trial results\",\"Diabetes\",\"HighTide Therapeutics\",\"HKG: 2511\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31813#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31813\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31813\",\"name\":\"HighTide Therapeutics' HTD1801 Shows Positive Phase III Results in Type 2 Diabetes Treatment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31813#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31813#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1504-png.webp\",\"datePublished\":\"2025-04-15T05:29:24+00:00\",\"dateModified\":\"2025-04-15T05:29:25+00:00\",\"description\":\"China-based HighTide Therapeutics Inc. (HKG: 2511) has announced positive results from two Phase III clinical studies (SYMPHONY-1 and SYMPHONY-2) for its drug candidate HTD1801 (berberine ursodeoxycholate, BUDCA) in treating type 2 diabetes (T2DM). Both studies achieved their primary endpoints, demonstrating significant improvements in glycemic control and supporting the filing of a New Drug Application (NDA) in China within this year.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31813#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31813\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31813#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1504-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1504-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"HighTide Therapeutics' HTD1801 Shows Positive Phase III Results in Type 2 Diabetes Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31813#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HighTide Therapeutics&#8217; HTD1801 Shows Positive Phase III Results in Type 2 Diabetes Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HighTide Therapeutics' HTD1801 Shows Positive Phase III Results in Type 2 Diabetes Treatment - Insight, China&#039;s Pharmaceutical Industry","description":"China-based HighTide Therapeutics Inc. (HKG: 2511) has announced positive results from two Phase III clinical studies (SYMPHONY-1 and SYMPHONY-2) for its drug candidate HTD1801 (berberine ursodeoxycholate, BUDCA) in treating type 2 diabetes (T2DM). Both studies achieved their primary endpoints, demonstrating significant improvements in glycemic control and supporting the filing of a New Drug Application (NDA) in China within this year.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31813","og_locale":"en_US","og_type":"article","og_title":"HighTide Therapeutics' HTD1801 Shows Positive Phase III Results in Type 2 Diabetes Treatment","og_description":"China-based HighTide Therapeutics Inc. (HKG: 2511) has announced positive results from two Phase III clinical studies (SYMPHONY-1 and SYMPHONY-2) for its drug candidate HTD1801 (berberine ursodeoxycholate, BUDCA) in treating type 2 diabetes (T2DM). Both studies achieved their primary endpoints, demonstrating significant improvements in glycemic control and supporting the filing of a New Drug Application (NDA) in China within this year.","og_url":"https:\/\/flcube.com\/?p=31813","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-15T05:29:24+00:00","article_modified_time":"2025-04-15T05:29:25+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1504-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31813#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31813"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HighTide Therapeutics&#8217; HTD1801 Shows Positive Phase III Results in Type 2 Diabetes Treatment","datePublished":"2025-04-15T05:29:24+00:00","dateModified":"2025-04-15T05:29:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31813"},"wordCount":291,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31813#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1504-png.webp","keywords":["Clinical trial results","Diabetes","HighTide Therapeutics","HKG: 2511"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31813#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31813","url":"https:\/\/flcube.com\/?p=31813","name":"HighTide Therapeutics' HTD1801 Shows Positive Phase III Results in Type 2 Diabetes Treatment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31813#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31813#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1504-png.webp","datePublished":"2025-04-15T05:29:24+00:00","dateModified":"2025-04-15T05:29:25+00:00","description":"China-based HighTide Therapeutics Inc. (HKG: 2511) has announced positive results from two Phase III clinical studies (SYMPHONY-1 and SYMPHONY-2) for its drug candidate HTD1801 (berberine ursodeoxycholate, BUDCA) in treating type 2 diabetes (T2DM). Both studies achieved their primary endpoints, demonstrating significant improvements in glycemic control and supporting the filing of a New Drug Application (NDA) in China within this year.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31813#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31813"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31813#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1504-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1504-png.webp","width":1080,"height":608,"caption":"HighTide Therapeutics' HTD1801 Shows Positive Phase III Results in Type 2 Diabetes Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31813#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HighTide Therapeutics&#8217; HTD1801 Shows Positive Phase III Results in Type 2 Diabetes Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1504-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31813","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31813"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31813\/revisions"}],"predecessor-version":[{"id":31815,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31813\/revisions\/31815"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31814"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31813"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31813"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31813"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}